세계의 인간 광견병 백신 시장 규모 : 세포주 유형별, 용도별, 유통 채널별, 지역 범위별 및 예측

Global Human Rabies Vaccines Market Size By Cell Line Type, By Application, By Distribution Channel, By Geographic Scope And Forecast

US $ 3,950 ￦ 5,411,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 4,850 ￦ 6,644,000

PDF & Excel (5 User License)

PDF 및 Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 7,550 ￦ 10,344,000

PDF & Excel (Enterprise User License)

PDF 및 Excel 보고서를 동일기업내 모든 분들이 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

한글목차

인간 광견병 백신 시장 규모 및 예측

인간 광견병 백신 시장 규모는 2024년에 12억 3,000만 달러로 평가되었고, 2026-2032년 연평균 5.7% 성장하여 2032년에는 19억 1,000만 달러에 달할 것으로 예측됩니다.

• 인간 광견병 백신은 인간이 광견병 바이러스에 감염되는 것을 예방하는 생물학적 제제입니다. 일반적으로 비활성화된 광견병 바이러스 입자 또는 바이러스에서 생성된 재조합 단백질로 구성됩니다.
• 이러한 백신 접종은 면역 체계를 자극하여 광견병 바이러스에 대한 항체를 형성하여 향후 광견병 바이러스에 노출되지 않도록 보호합니다.
• 인간 광견병 백신은 바이러스에 노출된 후 또는 수의사, 동물 관리 종사자, 광견병이 흔한 지역 여행자 등 광견병 동물과 마주칠 위험이 높은 사람에 대한 예방 조치로 보통 팔에 주사합니다.
• 또한, 인간 광견병 백신은 광견병 바이러스 감염으로 인한 치명적인 결과를 예방하는 데 중요한 역할을 하고 있습니다.

세계의 광견병 백신 시장 역학

인간 광견병 백신 시장을 형성하는 주요 시장 역학은 다음과 같습니다.

주요 시장 성장 촉진요인

• 세계 광견병 발병률 증가: 세계 광견병 발병률 증가: 주로 아시아와 아프리카에서 길고양이의 공격으로 인한 광견병 발병률이 전 세계적으로 급증하면서 인간 광견병 백신에 대한 수요가 급증하고 있습니다. 광견병 감염 예방 노력으로 인해 종합적인 백신 접종 프로그램이 요구되고 있으며, 이는 시장 확대의 원동력이 되고 있습니다.
• 정부의 이니셔티브와 예방접종 프로그램: 광견병을 근절하기 위해 세계 각국 정부는 광견병 예방접종 캠페인을 실시했습니다. 이러한 프로그램에서는 예방접종 무료화 및 보조금 지급이 자주 시행되고 있으며, 이는 인간 광견병 백신의 사용과 배포를 촉진하는 데 중요한 역할을 하고 있습니다.
• 백신 개발의 발전: 세포배양 백신과 재조합 백신 등 보다 효율적인 새로운 광견병 백신의 개발로 시장이 크게 성장하고 있습니다. 이러한 백신은 안전성과 유효성이 개선되어 더 많은 채택과 사용을 촉진하고 있습니다.
• 광견병 발생 지역 여행 및 노출 증가: 해외여행, 특히 광견병이 많이 발생하는 지역에서는 광견병에 감염될 가능성이 높아집니다. 이 때문에 여행자들 사이에서 노출 전 예방이 증가하여 인간 광견병 백신에 대한 수요가 증가하고 있습니다.

주요 과제

• 높은 비용과 접근성 문제: 광견병 백신은 고가이며, 외딴 지역이나 미개발 지역에서는 희소하기 때문에 큰 장애물이 되고 있습니다. 이러한 제약은 특히 광견병이 유행하고 예방접종이 가장 필요한 지역에서 중요한 예방접종 서비스에 대한 접근성을 제한하고 있습니다.
• 콜드체인 물류 및 보관: 광견병 백신은 보관 및 운송을 위한 콜드체인 시스템이 필요하지만, 특히 자원이 부족한 지역에서는 유지가 어렵습니다. 콜드체인이 끊어지면 백신의 효능이 떨어지기 때문에 대규모 예방접종 캠페인의 물류 장애가 되어 시장 확대가 제한됩니다.
• 인식 및 교육 부족: 많은 광견병 발병 지역에서는 광견병과 백신 접종의 중요성에 대한 인식이 낮습니다. 이러한 인식 부족으로 인해 기존 백신이 충분히 사용되지 않아 광견병 통제 및 근절 시도를 방해하고 있습니다.

주요 동향 :

• 세포배양 백신의 출현: 기존의 계란을 이용한 예방접종에 대한 대안으로 세포배양 백신의 인기가 높아지고 있습니다. 세포배양 백신은 더 안전하고 효과적이며 부작용이 적은 것으로 알려져 있으며, 노출 전 예방요법과 노출 후 요법 모두에서 인기가 높아지고 있습니다.
• 예방접종과 디지털 건강 기록의 통합: 광견병 예방접종을 포함한 예방접종 정보를 추적하기 위해 디지털 건강 플랫폼의 사용이 증가하고 있습니다. 이러한 통합은 백신 접종률과 일정 모니터링을 개선하고, 예방접종 프로그램의 효율성과 환자의 순응도를 향상시킬 수 있습니다.
• 백신 관련 민관협력(PPP) : 정부 및 헬스케어 그룹은 광견병 백신의 접근성과 구매 편의성을 향상시키기 위해 민간 백신 제조업체와 협약을 체결하고 있습니다. 이러한 PPP는 광견병 예방접종 프로그램을 소외된 사람들에게 확대하여 광견병 퇴치를 위한 전 세계의 노력을 강화하는 것을 목표로 하고 있습니다.
• 단회 접종 백신 연구에 집중: 연구 개발의 초점은 효과적인 단회 접종 광견병 백신 개발로 옮겨가고 있습니다. 단회 접종 백신은 예방접종 방법을 간소화하고, 순응도를 높이고, 노출 후 환경에서의 반응 시간을 단축시킬 수 있습니다.

목차

제1장 세계의 인간 광견병 백신 시장 서론

• 시장의 정의
• 시장 세분화
• 조사 스케줄
• 전제조건
• 제한 사항

제2장 VERIFIED MARKET RESEARCH의 조사 방법

• 데이터 마이닝
• 데이터 삼각측량
• 보텀업 접근
• 톱다운 접근
• 조사 흐름
• 업계 전문가의 주요 인사이트
• 데이터 소스

제3장 주요 요약

• 시장 개요
• 생태계 매핑
• 절대적 매출 기회
• 시장의 매력
• 세계의 인간 광견병 백신 시장 지역별 분석
• 세계의 인간 광견병 백신 시장 : 세포주 유형별
• 세계의 인간 광견병 백신 시장 : 용도별
• 세계의 인간 광견병 백신 시장 : 유통 채널별
• 향후 시장 기회
• 세계 시장 분할
• 제품 라이프라인

제4장 세계의 인간 광견병 백신 시장 전망

• 세계의 인간 광견병 백신 진화
• 성장 촉진요인
• 성장 억제요인
• 기회
• Porter's Five Forces 모델
• 밸류체인 분석
• 가격 분석
• 거시경제 분석

제5장 세계의 인간 광견병 백신 시장 : 세포주 유형별

• 개요
• 닭 배아세포
• 베로 세포
• BHK 세포
• 기타

제6장 세계의 인간 광견병 백신 시장 : 용도별

• 개요
• 노출 후 예방
• 노출 전 예방

제7장 세계의 광견병 백신 시장 : 유통 채널별

• 개요
• 병원 약국
• 소매 약국
• 온라인 채널

제8장 세계의 인간 광견병 백신 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 라틴아메리카
  • 다우·케미컬 브라질
  • 아르헨티나
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 아랍에미리트(UAE)
  • 사우디아라비아
  • 남아프리카공화국
  • 기타 중동 및 아프리카

제9장 세계의 인간 광견병 백신 시장 경쟁 구도

• 개요
• 기업의 시장 순위
• 주요 발전
• 기업의 지역별 실적
• 기업 산업별 실적
• ACE 매트릭스

제10장 기업 개요

• Sanofi Pasteur
• Merck & Co.
• GSK
• Bavarian Nordic A/S
• China National Biotec Group Co.
• Wuhan Institute of Biological Products Co.
• The Serum Institute of India Ltd.
• Bharat Biotech International Limited
• Valneva SE
• Virbac SA

제11장 주요 발전

• 제품 출시 및 개발
• 인수합병(M&A)
• 사업 확대
• 파트너십과 제휴

제12장 베리파이드·마켓·인텔리전스

• VERIFIED MARKET INTELLIGENCE에 대해
• 동적 데이터 시각화

LSH

영문 목차

영문목차

Human Rabies Vaccines Market Size And Forecast

Human Rabies Vaccines Market size was valued at USD 1.23 Billion in 2024 and is projected to reach USD 1.91 Billion by 2032, growing at a CAGR of 5.7% from 2026 to 2032.

• Human rabies vaccines are biologics that prevent humans from becoming infected with the rabies virus. They are usually composed of inactivated rabies virus particles or recombinant proteins produced from the virus.
• These vaccinations stimulate the immune system to develop antibodies against the rabies virus, protecting against future exposure.
• Human rabies vaccines are given in a series of injections, usually in the arm, after being exposed to the virus or as a preventive measure for people who are at high risk of encountering rabid animals, such as veterinarians, animal control workers, and travelers to areas where rabies is common.
• Moreover, human rabies vaccines play an important role in preventing the potentially lethal consequences of rabies virus infection.

Global Human Rabies Vaccines Market Dynamics

The key market dynamics that are shaping the Human Rabies Vaccines Market include:

Key Market Drivers:

• Growing Incidence of Rabies Worldwide: The global surge in rabies incidence, mainly in Asia and Africa as a result of stray dog attacks, has fueled demand for human rabies vaccines. Efforts to prevent rabies infections demand comprehensive vaccination programs, driving market expansion.
• Government Initiatives and Vaccination Programs: To eradicate rabies, governments around the world have started awareness and immunization campaigns. These programs frequently feature free or subsidized immunization, which is critical in promoting the use and distribution of human rabies vaccines.
• Advancements in Vaccine Development: The development of new and more efficient rabies vaccinations, such as cell culture and recombinant vaccines, has significantly boosted the market. These vaccines have improved safety and efficacy characteristics, encouraging greater adoption and use.
• Increased Travel and Exposure to Rabies-Prone Areas: There's a greater chance of contracting rabies when traveling internationally, particularly in regions where the disease is more common. This has resulted in an increase in pre-exposure prophylaxis among travelers, fueling the demand for human rabies vaccines.

Key Challenges:

• High Cost and Accessibility Issues: Rabies vaccines are expensive and scarce in remote or undeveloped areas, posing substantial obstacles. These constraints limit access to important vaccination services, particularly in locations where rabies is endemic and vaccinations are most needed.
• Cold Chain Logistics and Storage: Rabies vaccines necessitate a cold chain system for storage and transportation, which is challenging to maintain, particularly in low-resource areas. Breaks in the cold chain jeopardize vaccine efficacy, creating a logistical obstacle for extensive vaccination campaigns and limiting market expansion.
• Lack of Awareness and Education: Many rabies-endemic locations have a low level of awareness about the disease and the significance of vaccination. This lack of understanding resulted in the underuse of existing vaccines, impeding attempts to control and eradicate rabies.

Key Trends:

• Emergence of Cell Culture Vaccines: Cell culture vaccines are becoming increasingly popular as an alternative to traditional egg-based immunizations. Cell culture vaccines are seen as safer, more effective, and have fewer side effects, making them increasingly popular in both pre-exposure prophylactic and post-exposure therapies.
• Integration of Immunization with Digital Health Records: Digital health platforms are increasingly being utilized to track vaccination information, including rabies shots. This integration allows for improved monitoring of vaccine coverage and schedules, increasing the efficiency of immunization programs and patient compliance.
• Public-Private Partnerships (PPPs) for Vaccine Accessibility: Governments and healthcare groups are forging agreements with private-sector vaccine makers to improve rabies vaccine accessibility and affordability. These PPPs seek to expand immunization programs to underserved groups, thereby strengthening worldwide efforts to control and eliminate rabies.
• Focus on Research for Single-Dose Vaccines: Research and development efforts are increasingly centered on developing effective single-dose rabies vaccinations. A single-dose vaccine would simplify immunization methods, enhance compliance rates, and potentially accelerate response times in post-exposure settings, all of which would have a substantial impact on public health outcomes.

Global Human Rabies Vaccines Market Regional Analysis

Here is a more detailed regional analysis of the Human Rabies Vaccines Market:

Asia Pacific:

• According to Verified Market Research, Asia Pacific is estimated to dominate the Human Rabies Vaccines Market during the forecast period. Asia Pacific has some of the highest rates of rabies globally, partly due to massive stray dog populations in countries like India and China. This high frequency creates a significant need for human rabies vaccines, making the region an important market for these products.
• Governments in the Asia Pacific region have initiated aggressive rabies control and elimination programs, including mass vaccination of animals and humans. These measures considerably contribute to increased demand for rabies vaccines, which strengthens the market in this region.
• In the Asia Pacific region, public awareness of rabies and its prevention is increasing, due in part to educational efforts launched by health organizations and governments. This increased awareness has resulted in greater vaccination rates, which is fueling the market's growth.
• Furthermore, the Asia Pacific region's rapid development and extension of healthcare infrastructure, including increasing healthcare spending and the formation of new healthcare institutions, has expanded public access to vaccines. This infrastructure expansion enables more widespread distribution and administration of rabies vaccines.

Latin America:

• The expansion of urban areas in Latin America has resulted in more pet ownership and interaction with wildlife, increasing the danger of rabies spread. This tendency increases demand for pre-exposure prophylactic and post-exposure therapies, hence expanding the Human Rabies Vaccines Market.
• Many Latin American countries have carried out large rabies vaccination efforts for both animals and humans, particularly in rural and urban peripheral areas. These government-led programs are critical drivers of increased demand and distribution of rabies vaccines throughout the region.
• Furthermore, in Latin American countries, the growth of healthcare services and improved access to medical care have permitted increased vaccination coverage. This includes rural healthcare programs and the creation of clinics in underserved areas, which will drive the demand for rabies vaccines by making them more accessible to a larger population.

Middle East & Africa:

• The Middle East and Africa region has a high incidence of rabies cases, mostly due to stray dog populations and animals. This prevalence needs the continued and growing use of rabies vaccines, which drives market growth in both preventive and post-exposure therapies.
• Several nations in the region have initiated attempts to eradicate rabies, such as mass vaccination of animals and public health campaigns urging immunization. These initiatives by governmental and non-governmental organizations have considerably increased the demand for human rabies vaccines.
• Furthermore, International health organizations and philanthropists are increasingly sponsoring rabies prevention and control projects throughout the Middle East and Africa. This external financing and technical aid make vaccine procurement and distribution easier, increasing the region's ability to effectively combat rabies.

Global Human Rabies Vaccines Market: Segmentation Analysis

The Global Human Rabies Vaccines Market is segmented based on Cell Line Type, Application, Distribution Channel, And Geography.

Human Rabies Vaccines Market, By Cell Line Type

• Chick Embryo Cell
• Vero Cell
• BHK Cell
• Others

Based on Cell Line Type, the market is segmented into Chick Embryo Cells, Vero Cells, BHK Cells, and Others. The chick embryo cell segment is estimated to dominate the Human Rabies Vaccines Market due to the long-standing usage of chick embryo cells in the manufacture of rabies vaccines, which are known for their efficacy and safety. Vaccines made from chick embryo cell culture are widely used in immunization programs around the world, thanks in part to their long history of usage and thorough safety data. Furthermore, the synthesis procedure employing chick embryo cells is cost-effective and well-optimized, making these vaccines accessible and economical for large-scale immunization programs, particularly in underdeveloped countries where rabies is prevalent.

Human Rabies Vaccines Market, By Application

• Post-exposure Prophylaxis
• Pre-exposure Prophylaxis

Based on Application, the market is segmented into Post-exposure Prophylaxis and Pre-exposure Prophylaxis. The post-exposure prophylaxis segment is estimated to dominate the Human Rabies Vaccines Market during the forecast period due to the critical requirement for rabies vaccination following potential exposure to the rabies virus, which can be acquired by bites or scratches from infected animals. In many areas, particularly those where rabies is endemic, the danger of exposure is considerable, demanding early treatment to avoid the development of the disease, which is almost invariably fatal once symptoms appear. Post-exposure prophylaxis (PEP) entails delivering the rabies vaccination soon after exposure to prevent the virus from developing into an active disease.

Human Rabies Vaccines Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Channel

Based on the Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Channel. The hospital pharmacies segment is estimated to dominate the Human Rabies Vaccines Market during the forecast period due to the essential role hospital pharmacists play in administering post-exposure prophylaxis (PEP), which needs prompt medical attention. Hospitals are the major treatment locations for rabies exposures because they can give both the vaccination and the required immunoglobulins, as well as skilled medical monitoring. Furthermore, in many locations, rabies vaccines are provided as part of government-led health campaigns, with hospitals serving as the primary distribution and administration sites.

Key Players

• The "Human Rabies Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Sanofi Pasteur, Merck & Co., GSK, Bavarian Nordic A/S, China National Biotec Group Co., Wuhan Institute of Biological Products Co., The Serum Institute of India Ltd., Bharat Biotech International Limited, Valneva SE, Virbac SA, Crucell NV, Institute of Viral Diseases and CanSino Biologics Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Human Rabies Vaccines Market Recent Developments
• In December 2022, Everest Medicines announced the launch of a novel mRNA Rabies Vaccine development and the completion of a preclinical proof-of-concept study. This is a collaboration with Providence Therapeutics that focuses on a new rabies vaccine candidate.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HUMAN RABIES VACCINES MARKET

• 1.1 Market Definition
• 1.2 Market Segmentation
• 1.3 Research Timelines
• 1.4 Assumptions
• 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 2.1 Data Mining
• 2.2 Data Triangulation
• 2.3 Bottom-Up Approach
• 2.4 Top-Down Approach
• 2.5 Research Flow
• 2.6 Key Insights from Industry Experts
• 2.7 Data Sources

3 EXECUTIVE SUMMARY

• 3.1 Market Overview
• 3.2 Ecology Mapping
• 3.3 Absolute Market Opportunity
• 3.4 Market Attractiveness
• 3.5 Global Human Rabies Vaccines Market Geographical Analysis (CAGR %)
• 3.6 Global Human Rabies Vaccines Market, By Cell Line Type (USD Million)
• 3.7 Global Human Rabies Vaccines Market, By Application (USD Million)
• 3.8 Global Human Rabies Vaccines Market, By Distribution Channel (USD Million)
• 3.9 Future Market Opportunities
• 3.10 Global Market Split
• 3.11 Product Life Line

4 GLOBAL HUMAN RABIES VACCINES MARKET OUTLOOK

• 4.1 Global Human Rabies Vaccines Evolution
• 4.2 Drivers
  • 4.2.1 Driver1
  • 4.2.2 Driver 2
• 4.3 Restraints
  • 4.3.1 Restraint1
  • 4.3.2 Restraint 2
• 4.4 Opportunities
  • 4.4.1 Opportunity1
  • 4.4.2 Opportunity 2
• 4.5 Porters Five Force Model
• 4.6 Value Chain Analysis
• 4.7 Pricing Analysis
• 4.8 Macroeconomic Analysis

5 GLOBAL HUMAN RABIES VACCINES MARKET, BY CELL LINE TYPE

• 5.1 Overview
• 5.2 Chick Embryo Cell
• 5.3 Vero Cell
• 5.4 BHK Cell
• 5.5 Others

6 GLOBAL HUMAN RABIES VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Post-exposure Prophylaxis
• 6.3 Pre-exposure Prophylaxis

7 GLOBAL HUMAN RABIES VACCINES MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Channel

8 GLOBAL HUMAN RABIES VACCINES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Dow Chemical Company Brazil
  • 8.5.2 Argentina
  • 8.5.3 Rest of Latin America
• 8.6 Middle-East and Africa
  • 8.6.1 UAE
  • 8.6.2 Saudi Arabia
  • 8.6.3 South Africa
  • 8.6.4 Rest of Middle-East and Africa

9 GLOBAL HUMAN RABIES VACCINES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Developments
• 9.4 Company Regional Footprint
• 9.5 Company Industry Footprint
• 9.6 ACE Matrix

10 COMPANY PROFILES

• 10.1 Sanofi Pasteur
  • 10.1.1 Company Overview
  • 10.1.2 Company Insights
  • 10.1.3 Product Benchmarking
  • 10.1.4 Key Developments
• 10.2 Merck & Co.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 GSK
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Bavarian Nordic A/S
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 China National Biotec Group Co.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Wuhan Institute of Biological Products Co.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 The Serum Institute of India Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Bharat Biotech International Limited
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Valneva SE
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Virbac SA
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12. VERIFIED MARKET INTELLIGENCE

• 12.1 About Verified Market Intelligence
• 12.2 Dynamic Data Visualization

관련자료